Evidence map›Paper›PMID 38811421›Full record

ArticleBasic research in cardiology2024

Targeting Gα

David Köhler, Veronika Leiss, Lukas Beichert, Simon Killinger, Daniela Grothe, Ragini Kushwaha, Agnes Schröter, Anna Roslan, Claudia Eggstein, Jule Focken and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Basic research in cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

David Köhler *Department of Anesthesiology and Intensive Care Medicine, Eberhard Karls University, Tübingen, Germany.
Veronika Leiss *Department of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Lukas BeichertDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Simon KillingerDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Daniela GrotheDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Ragini KushwahaDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Agnes SchröterDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Anna RoslanDepartment of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany.
Claudia EggsteinDepartment of Anesthesiology and Intensive Care Medicine, Eberhard Karls University, Tübingen, Germany.
Jule FockenDivision of Dermatooncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
Tiago GranjaDepartment of Anesthesiology and Intensive Care Medicine, Eberhard Karls University, Tübingen, Germany.
Vasudharani DevanathanDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Birgit SchittekDivision of Dermatooncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
Robert LukowskiDepartment of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany.
Bettina WeigelinDepartment of Preclinical Imaging and Radiopharmacy, Multiscale Immunoimaging, Eberhard Karls University, Tübingen, Germany.
Peter RosenbergerDepartment of Anesthesiology and Intensive Care Medicine, Eberhard Karls University, Tübingen, Germany.
Bernd NürnbergDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany.
Sandra Beer-HammerDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Eberhard Karls University, and Interfaculty Center of Pharmacogenomic and Drug Research, Wilhelmstrasse 56, 72074, Tübingen, Germany. sandra.beer-hammer@uni-tuebingen.de.ORCID 0000-0001-6049-0257

Funding

Deutsche Forschungsgemeinschaft EXC2124Deutsche Forschungsgemeinschaft EXC2180Deutsche Forschungsgemeinschaft RTG 2816Deutsche Forschungsgemeinschaft TR156Medical Faculty Eberhard-Karls-University Tübingen 2561-0-0Medizinische Fakultät, Universität Tübingen start-up funding to establish DFG RTG 2816
6 · The paper itself

Abstract

Neutrophils are not only involved in immune defense against infection but also contribute to the exacerbation of tissue damage after ischemia and reperfusion. We have previously shown that genetic ablation of regulatory Gα

Indexed as

GTP-Binding Protein alpha Subunit, Gi2Mice, KnockoutMyocardial Reperfusion InjuryNeutrophilsAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLSignal TransductionGnai2 protein, mouseGTP-Binding Protein alpha Subunit, Gi2Cardiac ischemia reperfusion injuryEndothelial transmigrationG-protein-coupled receptorsNeutrophil

Identifiers

PMID38811421
PMCPMC11461587

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.